Abstract
Pravastatin reduce pro-inflammatory mediators in feto-maternal interface (FMi) tissues and minimize PE-like symptoms in vitro and in animal models. Several questions remain regarding the drug’s pharmacokinetics (PK), metabolism, and efficacy that cannot be fully answered using traditional 2D cell culture or placental perfusion models prior to clinical trials. We used two distinct microfluidic organ-on-chip (OOC) models that are interconnected through microchannels and maintain intercellular interactions between cells to faithfully represents the human FMi to test pravastatin’s PK and cellular responses at the fetal membranes (FM) and placenta (P).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
